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SPARC is a glycoprotein from the extracellular matrix normally expressed during 
development and in wound healing. SPARC is also overexpressed in different tumors, 
in association with tumor progression. We have showed that downregulation of SPARC 
expression by antisense and RNAi techniques in human melanoma cells abolished 
tumorigenicity in an in vivo immunodeficient murine model, through still not clear 
molecular mechanisms. In the pursuit of molecular mediators of SPARC activity that 
may explain its role in tumor progression, we have performed a proteomic analysis 
of proteins secreted by L2F6 clone cells (MEL-LES human melanoma cells with 
RNAi-mediated inhibition of SPARC expression) and compared it to its control cell 
line LBLAST. Overall, around 12% of detected spots in conditioned media were 
significantly up- or down-regulated by changes in expression levels of SPARC. After 
identification of differential spots using MALDI-TOF/TOF, a selected group of these 
proteins was chosen for technical, biological and functional validation. Differences 
in these proteins were confirmed not only in the aforementioned cells but also using 
transient (i.e. adenoviral) restoration of SPARC expression on MEL-LES cells. Most 
interestingly, several of the validated proteins are well-known mediators of tumor 
progression but were not previously related to SPARC. In particular, we have collected 
experimental evidence that confirm the role of SPARC as an important inductor of 
proteins involved in tumor invasion. Our results constitute the first evidence that 
SPARC and these proteins may participate in a single molecular network that leads to 
tumor progression.
